Alexion Pharmaceuticals, AstraZeneca’s rare disease unit, shined a light on neuromyelitis optica spectrum disorder (NMOSD), a severe neurological disease, in a short film that debuted Thursday. While ...
WILMINGTON, Del.--(BUSINESS WIRE)--Alexion, AstraZeneca Rare Disease, will showcase the potential for its pioneering therapies to redefine the treatment landscape for certain rare neurological ...
AstraZeneca is making new progress with its Ultomiris expansion plan. On the heels of an FDA approval, the C5 inhibitor has returned with a clinical win in a rare autoimmune disease affecting the ...
The agreement is a critical step in ensuring adult patients living with NMOSD and gMG have public access to Ultomiris MISSISSAUGA, ON, Aug. 7, 2025 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's ...
– Data highlight long-term and real-world efficacy of SOLIRIS® (eculizumab) in patients living with rare neurologic complement-mediated disorders, including neuromyelitis optica spectrum disorder ...
Please provide your email address to receive an email when new articles are posted on . Ultomiris is a C5 complement inhibitor for neuromyelitis optica spectrum disorder. Trial patients did not ...
Please provide your email address to receive an email when new articles are posted on . Treatment with inebilizumab was effective in reducing two telltale signs of an attack of neuromyelitis optica ...
BARCELONA, Spain — Use of ravulizumab for long-term treatment of neuromyelitis optica spectrum disorder (NMOSD) offered sustained protection from relapse for at least 3 years, results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results